The global genitourinary drugs market is accounted for USD 28,200 million expected and expected to register CAGR ~1.65% during the forecast period (2018–2023).
Genitourinary disorders are caused by damage to urinal or genital part of the human body. Kidney, bladder, ureter and urethra are parts of genitourinary system, genitourinary drugs are used to treat the medical complications caused to these parts. The rising prevalence of genitourinary disorders, increasing number of pipeline drugs, and technological advancement in genitourinary diagnosis are expected to drive the growth of the market. According to the U.S. National Library of Medicine more than 480 clinical trials are lined up for treatment of urinary tract infection.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6802
Health Information Center, Moreover, rising R&D spending and collaborative strategies adopted by the top players such as licensing and agreements are contributing to the growth of the market. For instance, in October 2018, Novartis AG signed a licensing agreement with Boston Pharmaceuticals for manufacturing and marketing of its three anti-infective products LYS228, IID572, and MAK181.
The increasing emergence of counterfeit drugs, rising generics drug competition, and high number of patent expirations may hamper the growth of the market during the assessment period.
Segmentation
The global genitourinary drugs market has been segmented on the basis of disease, product, and end-user.
On the basis of disease, the market has been classified urinary tract infections, erectile dysfunction, urinary incontinence & overactive bladder, kidney/renal cancer, genitourinary cancer, bladder cancer, bladder cancer, cervical cancer, sexually transmitted diseases, interstitial cystitis, hematuria, ovarian cancer, prostate cancer, and others.
The product segment has been divided into urologicals, hormonal therapy, gynecologicals, and anti-infectives.
The market, by end-user, has been segmented into hospitals, clinics, super specialty centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The genitourinary drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European genitourinary drugs market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The genitourinary drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The genitourinary drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas are likely to dominate the global genitourinary drugs market owing to the rising prevalence of genitourinary disorders in aging population, increase in the healthcare expenditure, and the presence of a well-established healthcare system. According to the National Kidney Foundation, Urinary tract infections (UTIs) are responsible for nearly 10 million doctor visits each year and approximately 20% women suffer from UTI at least once in a life.
The European market is expected to be the second-largest genitourinary drugs market. The market growth in this region can be attributed to the increasing research and development, rise in number of chronic diseases such as diabetes, and government initiatives for the development of healthcare sector. According to the International Diabetes Foundation, diabetes is major health concern in European region and in 2017, approximately 9.1% of total European population was suffering from diabetes.
Asia-Pacific is expected to be the fastest-growing genitourinary drugs market during the forecast period owing to the increasing geriatric production along with rise in number of genitourinary disorders, rising investments in healthcare and expansions by market players in the region. According to United Nations, Department of Economic and Social Affairs, in 2016, 12.4% of total population in Asian countries was 60 year or older.
The market in the Middle East & Africa is expected to hold the smallest share of the global genitourinary drugs market due to lack of technical knowledge, undeveloped healthcare sector, and poor medical facilities.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/genitourinary-drugs-market-6802
No comments:
Post a Comment